C
Claire Dearden
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 151
Citations - 6002
Claire Dearden is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Alemtuzumab & Chronic lymphocytic leukemia. The author has an hindex of 36, co-authored 140 publications receiving 5200 citations.
Papers
More filters
Journal ArticleDOI
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
TL;DR: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Journal ArticleDOI
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
David Gonzalez,Pilar Alejandra Saiz Martínez,Rachel Wade,Sarah L. Hockley,David Oscier,Estella Matutes,Claire Dearden,Sue Richards,Daniel Catovsky,Gareth J. Morgan +9 more
TL;DR: Analysis of TP53 mutations should be performed in patients with CLL who have progressive disease before starting first-line treatment, and those with mutations should been selected for novel experimental therapies.
Journal ArticleDOI
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia
Helen E. Speedy,Maria Chiara Di Bernardo,Georgina P. Sava,Martin J. S. Dyer,Amy Holroyd,Yufei Wang,Nicola J. Sunter,Larry Mansouri,Gunnar Juliusson,Karin E. Smedby,Göran Roos,Sandrine Jayne,Aneela Majid,Claire Dearden,Andrew G. Hall,Tryfonia Mainou-Fowler,Graham Jackson,Geoffrey Summerfield,Robert J. Harris,Andrew R. Pettitt,David Allsup,James R. Bailey,Guy Pratt,Chris Pepper,Christopher Fegan,Richard Rosenquist,Daniel Catovsky,James M. Allan,Richard S. Houlston +28 more
TL;DR: A genome-wide association study of chronic lymphocytic leukemia and a meta-analysis with a published GWAS identified new susceptibility loci and validated recently reported putative associations at 5p15.33, providing further insights into the genetic and biological basis of inherited genetic susceptibility to CLL.
Journal ArticleDOI
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Michael R. Grever,Omar Abdel-Wahab,Leslie A. Andritsos,Versha Banerji,Jacqueline C. Barrientos,James S. Blachly,Timothy G. Call,Daniel Catovsky,Claire Dearden,Judit Demeter,Monica Else,Francesco Forconi,Alessandro Gozzetti,Anthony D. Ho,James B. Johnston,Jeffrey A. Jones,Gunnar Juliusson,Eric H. Kraut,Robert J. Kreitman,Loree Larratt,Francesco Lauria,Gerard Lozanski,Emili Montserrat,Sameer A. Parikh,Jae-Hyun Park,Aaron Polliack,Graeme R. Quest,Kanti R. Rai,Farhad Ravandi,Tadeusz Robak,Alan Saven,John F. Seymour,Tamar Tadmor,Martin S. Tallman,Constantine S. Tam,Enrico Tiacci,Xavier Troussard,Clive S. Zent,Thorsten Zenz,Pier Luigi Zinzani,Brunangelo Falini +40 more
TL;DR: The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients, and organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research.
Journal ArticleDOI
Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases
TL;DR: The natural history and response to treatment in 50 patients with splenic lymphoma with villous lymphocytes followed for a minimum of 6 months and up to 15 years was studied.